
PSA screening cuts prostate cancer deaths but benefits are modest and risks exist
A large Cochrane review of six PSA screening trials (nearly 800,000 men) finds PSA testing can reduce prostate cancer deaths, but the absolute benefit is small (about 2 lives saved per 1,000 screened; 500 men need screening to prevent one death). Benefits emerge only with long follow-up, while many men face overdiagnosis and potential harms from treatment, such as incontinence or erectile dysfunction. The authors caution against universal screening and emphasize shared decision making, with targeted approaches for high-risk groups and ongoing development of MRI- and biomarker–based methods whose extra benefit remains uncertain.













